Skip to main content
Signal8

Gilead Sciences Announces Third Quarter 2026 Financial Results

$GILDPress releaseOct 29, 2026, 4:02 PM ETRead the release

Gilead reported Q3 2026 total revenues of $8.30 billion (+7% YoY), with product sales ex-Veklury up 16% to $8.2 billion — its strongest base-business growth in over a decade. HIV sales rose 18% to $6.25 billion, with Descovy up 49% and Yeztugo scaling to $305 million; Trodelvy grew 42% to $506 million, while Veklury (-69%) and Cell Therapy (-18%) declined. GAAP diluted EPS was $1.94 and non-GAAP EPS $2.55. FY26 product sales guidance was raised to $31.0B-$31.3B from $30.1B-$30.4B, the second raise of the year totaling $1.6 billion since the start of 2026.

Key figures

Eps
1.94
Revenue
8300000000
Guidance
FY26 product sales $31.0B-$31.3B (raised from $30.1B-$30.4B); product sales ex-Veklury $30.7B-$31.0B; GAAP diluted loss per share $(4.40)-$(4.05); non-GAAP diluted loss per share $(1.20)-$(0.85)
Revenue Yoy
7%
Hiv sales
6249000000
Non gaap eps
2.55
Descovy sales
1046000000
Hiv sales yoy
18%
Veklury sales
86000000
Biktarvy sales
4100000000
Free cash flow
4798000000
Trodelvy sales
506000000
Iprd charges ytd
12400000000
Descovy sales yoy
49%
Veklury sales yoy
-69%
Biktarvy sales yoy
10%
Cell therapy sales
355000000
Dividend per share
0.82
Trodelvy sales yoy
42%
Operating cash flow
5035000000
Product gross margin
81.0%
Cell therapy sales yoy
-18%
Product sales ex veklury
8203000000
Product sales ex veklury yoy
16%
Non gaap product gross margin
88.1%
Cash and marketable securities
6437000000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.